Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Bao, Weike ^a   Aravindhan, Karpagam ^a   Alsaid, Hasan ^a   Chendrimada, Thimmaiah ^a   Szapacs, Matthew ^a   Citerone, David R ^a   Harpel, Mark R ^a   Willette, Robert N ^a   Lepore, John J ^a   Jucker, Beat M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; CARBOHYDRATE; GLUCOSE; INSULIN; LACTIC ACID; CARDIOTONIC AGENT; CYCLIC AMP; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; EX VIVO STUDY; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; INSULIN BLOOD LEVEL; LACTATE BLOOD LEVEL; MALE; NONHUMAN; OXIDATION; RAT; REPERFUSION INJURY; UPREGULATION; ANIMAL; BLOOD; DRUG EFFECT; ENERGY METABOLISM; FEEDING BEHAVIOR; GENETIC TRANSCRIPTION; GENETICS; HEART; HEART FUNCTION TEST; HEART INFARCTION; HEART MUSCLE; HEMODYNAMICS; IN VITRO STUDY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PRINCIPAL COMPONENT ANALYSIS; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARDIOTONIC AGENTS; CYCLIC AMP; ENERGY METABOLISM; FEEDING BEHAVIOR; GLUCAGON-LIKE PEPTIDE 1; HEART; HEART FUNCTION TESTS; HEMODYNAMICS; INSULIN; LACTIC ACID; MALE; METABOLIC NETWORKS AND PATHWAYS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION, GENETIC;

EID: 80052072913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023570     Document Type: Article

References (38)

1. Baggio LL, Drucker DJ, (2007) Biology of incretins GLP-1 and GIP. Gastroenterology 132: 2131-2157.
2. Barnett AH, (2009) New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf) 70: 343-353.
3. Grieve DJ, Cassidy RS, Green BD, (2009) Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157: 1340-1351.
4. Bose AK, Mocanu MM, Carr RD, Yellon DM, (2005) Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19: 9-11.
5. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM, (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151.
6. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, et al. (2006) Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317: 1106-1113.
7. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, et al. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117: 2340-2350.
8. Pratley RE, (2008) Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 10: 171.
9. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, et al. (2009) Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510.
10. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, et al. (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983.
11. Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, et al. (2009) Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 9: 31.
12. Luptak I, Yan J, Cui L, Jain M, Liao R, et al. (2007) Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress. Circulation 116: 901-909.
13. Nikolaidis LA, Elahi D, Shen YT, Shannon RP, (2005) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-H2408.
14. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, et al. (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965.
15. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, et al. (2008) Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 93: 4810-4817.
16. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, et al. (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961.
17. Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, et al. (2009) Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 11: 498-505.
18. St Onge EL, Miller SA, (2010) Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin Biol Ther 10: 801-806.
19. Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, et al. (2008) In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J Pharmacol Exp Ther 325: 466-474.
20. Bao W, Hu E, Tao L, Boyce R, Mirabile R, et al. (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61: 548-558.
21. Wetter TJ, Gazdag AC, Dean DJ, Cartee GD, (1999) Effect of calorie restriction on in vivo glucose metabolism by individual tissues in rats. Am J Physiol 276: E728-E738.
22. Kraegen EW, James DE, Jenkins AB, Chisholm DJ, et al. (1985) Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 248: E353-E362.
23. Willette RN, Bao W, Nerurkar S, Yue TL, Doe CP, et al. (2008) Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2. J Pharmacol Exp Ther 326: 443-452.
24. Jucker BM, Rennings AJ, Cline GW, Petersen KF, Shulman GI, (1997) In vivo NMR investigation of intramuscular glucose metabolism in conscious rats. Am J Physiol 273: E139-E148.
25. Jucker BM, Rennings AJ, Cline GW, Shulman GI, (1997) 13C and 31P NMR studies on the effects of increased plasma free fatty acids on intramuscular glucose metabolism in the awake rat. J Biol Chem 272: 10464-10473.
26. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, et al. (2003) Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108: 2393-2399.
27. Taylor DJ, Styles P, Matthews PM, Arnold DA, Gadian DG, et al. (1986) Energetics of human muscle: exercise-induced ATP depletion. Magn Reson Med 3: 44-54.
28. Bloch G, Chase JR, Avison MJ, Shulman RG, (1993) In vivo 31P NMR measurement of glucose-6-phosphate in the rat muscle after exercise. Magn Reson Med 30: 347-350.
29. Bradley DP, Kulstad R, Schoeller DA, (2010) Exenatide and weight loss. Nutrition 26: 243-249.
30. Reffelmann T, Hale SL, Li G, Kloner RA, (2002) Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol 282: H766-H772.
31. Schwarz ER, Somoano Y, Hale SL, Kloner RA, (2000) What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat? J Thromb Thrombolysis 10: 181-187.
32. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, et al. (2008) Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 1: 153-160.
33. Makinde AO, Kantor PF, Lopaschuk GD, (1998) Maturation of fatty acid and carbohydrate metabolism in the newborn heart. Mol Cell Biochem 188 (1-2): 49-56.
34. Aguilar D, (2008) Management of type 2 diabetes in patients with heart failure. Curr Treat Options Cardiovasc Med 10: 465-475.
35. Abozguia K, Clarke K, Lee L, Frenneaux M, (2006) Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 3: 490-498.
36. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, et al. (1992) 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86: 1810-1818.
37. Gropler RJ, Beanlands RS, Dilsizian V, Lewandowski ED, Villanueva FS, et al. (2010) Imaging myocardial metabolic remodeling. J Nucl Med 51 (Suppl 1): 88S-101S.
38. Poole-Wilson PA, (1989) Regulation of intracellular pH in the myocardium; relevance to pathology. Mol Cell Biochem 89 (2): 151-155.